Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab Plus Irinotecan in KRAS Wild-Type Metastatic Colorectal Cancer
NCT00972465Phase 2Unknown
- Sponsor
- Peking University
- Start
- Jun 2009
- Primary completion
- Dec 2009
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nimotuzumab in colorectal cancer (metastatic) (mCRC), sponsored by Peking University. Status: unknown.
02
Drugs
nimotuzumab
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT00972465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00972465.